Research programme: nanoparticle therapeutics - Cristal Therapeutics

Drug Profile

Research programme: nanoparticle therapeutics - Cristal Therapeutics

Alternative Names: CriPec Actively Targeted Nanoparticles - Cristal Therapeutics; CriPec ATN - Cristal Therapeutics; CriPec oligonucleotides - Cristal Therapeutics; CriPec® DUO; CriPec® dexamethasone; CriPec® DUO - Cristal Therapeutics; CriPec® peptides - Cristal Therapeutics; Dexamethasone nanoparticle - Cristal therapeutics; Exenatide nanoparticle - Cristal Therapeutics; Leuprolide nanoparticle - Cristal Therapeutics; Octreotide nanoparticle - Cristal Therapeutics

Latest Information Update: 27 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cristal Therapeutics
  • Class Fluorinated steroids; Glucocorticoids; Peptides; Pregnadienetriols
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammation; Solid tumours

Most Recent Events

  • 27 Jan 2016 Research programme: nanoparticle therapeutics - Cristal Therapeutics is available for licensing as of 27 Jan 2016.
  • 27 Jan 2016 Cristal Therapeutics has patent protection for drug delivery systems prepared using CriPec Technology (Cristal Therapeutics website, January 2016)
  • 25 Jan 2016 Early research in Solid tumours in Netherlands (IV) prior to January 2016 (Cristal Therapeutics pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top